Overview |
bs-12144R |
SHC2/Sck Polyclonal Antibody |
ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC |
Human, Mouse, Rat, Dog, Cow, Sheep |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated synthetic peptide derived from human SHC2/Sck |
161-270/582 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
Cytoplasm, Cell membrane |
Protein Sck; SCK; SH2 domain protein C2; SHC transforming protein 2; SHCB; Src homology 2 domain containing transforming protein C2; SHC2_HUMAN. |
Src homology 2 (SH2) domains bind specifically to tyrosine-phosphorylated proteins that temporally participate in signal transduction events (1). Shc-like protein (Sck) is a neuronal adaptor protein that contains an N-terminal PTB (phosphotyrosine binding) domain, a collagen homology (CH) domain, and a conserved C-terminal SH2 domain (2,3). Human Sck transcripts are present at high levels in liver, pancreas, prostate and ovary (4,5). In vascular endothelial cells, Sck participates in VEGF-induced signal transduction (6). Treatment of human umbilical vein endothelial (HUVEC) cells with VEGF induces recruitment of Sck to tyrosine-1175 of the kinase insert domain-containing receptor (KDR) and enhances Sck tyrosine phosphorylation (7,8). |
Application Dilution |
ELISA |
1:500-1000 |
IHC-P |
1:200-400 |
IHC-F |
1:100-500 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |
ICC |
1:100-500 |